Literature DB >> 11877261

Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?

Nichola Cooper1, B Michael R Woloski, Erin M Fodero, Maria Novoa, Melissa Leber, Juerg H Beer, James B Bussel.   

Abstract

This study explored whether repeated infusions of intravenous anti-D could allow adults with recently diagnosed immune thrombocytopenic purpura (ITP) who had failed an initial steroid course to postpone and ultimately avoid splenectomy. Twenty-eight Rh(+), nonsplenectomized adults with ITP diagnosed within 1 to 11 months and platelet counts 30 x 10(9)/L (30 000/microL) or below were enrolled. Anti-D was infused whenever the platelet count decreased to 30 x 10(9)/L (30 000/microL) or below. "Response" was defined as a platelet increase of more than 20 x 10(9)/L (20 000/microL) to more than 30 x 10(9)/L (30 000/microL) within 7 days of treatment. Patients were a median 3.5 months from ITP diagnosis at enrollment and had received a median of 2 previous therapies, including prednisone in 26 of 28 cases. They were followed for a median 26 months. A total of 93% responded to their initial infusion of anti-D, and 68% repeatedly responded with counts maintained above 30 x 10(9)/L (30 000/microL) using anti-D alone. Currently, 12 (43%) of 28 patients have been off all treatment for more than 6 months without undergoing splenectomy, 6 maintaining counts above 100 x 10(9)/L (100 000/microL). Seven continue on treatment, 8 underwent splenectomy, and 1 was lost to follow-up at 10 months. One patient discontinued anti-D because of toxicity. Patients with platelet counts at least 14 x 10(9)/L (14 000/microL) at enrollment were more likely to discontinue treatment (P <.05). Anti-D was an effective maintenance treatment for two thirds of Rh(+), nonsplenectomized adults with ITP who had failed an initial steroid course. Intermittent infusions of intravenous anti-D allowed more than 40% of these adults to avoid splenectomy and to achieve stable platelet counts off all therapy, even after many months of treatment. Platelet count at study entry was the primary predictor of outcome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11877261     DOI: 10.1182/blood.v99.6.1922

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  [Adult autoimmune thrombocytopenia: diagnosis and treatment].

Authors:  Klaus Lechner; Ansgar Weltermann; Ingrid Pabinger
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

Review 2.  Pathophysiology and therapeutic options in primary immune thrombocytopenia.

Authors:  Roberto Stasi
Journal:  Blood Transfus       Date:  2010-11-26       Impact factor: 3.443

3.  Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.

Authors:  Tomás José González-López; Fernando Fernández-Fuertes; José Angel Hernández-Rivas; Blanca Sánchez-González; Violeta Martínez-Robles; María Teresa Alvarez-Román; Gloria Pérez-Rus; Cristina Pascual; Silvia Bernat; Esther Arrieta-Cerdán; Carlos Aguilar; Abelardo Bárez; María Jesús Peñarrubia; Pavel Olivera; Angeles Fernández-Rodríguez; Erik de Cabo; Luis Javier García-Frade; José Ramón González-Porras
Journal:  Int J Hematol       Date:  2017-06-30       Impact factor: 2.490

Review 4.  Immune thrombocytopenia.

Authors:  Gaurav Kistangari; Keith R McCrae
Journal:  Hematol Oncol Clin North Am       Date:  2013-06       Impact factor: 3.722

5.  Prediction of response to splenectomy in patients with idiopathic thrombocytopenic purpura.

Authors:  A Shojaiefard; S A Mousavi; S H Faghihi; S Abdollahzade
Journal:  World J Surg       Date:  2008-03       Impact factor: 3.352

6.  Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective.

Authors:  Susan D Mathias; Sue K Gao; Kimberly L Miller; David Cella; Claire Snyder; Ralph Turner; Albert Wu; James B Bussel; James N George; Robert McMillan; Diane Kholos Wysocki; Janet L Nichol
Journal:  Health Qual Life Outcomes       Date:  2008-02-08       Impact factor: 3.186

7.  Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia.

Authors:  Eric Cheung; Howard A Liebman
Journal:  Biologics       Date:  2009-07-13

Review 8.  Current Management of Primary Immune Thrombocytopenia.

Authors:  Drew Provan; Adrian C Newland
Journal:  Adv Ther       Date:  2015-10-26       Impact factor: 3.845

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.